{"title":"肺炎链球菌分离株中利奈唑胺耐药性的流行情况：系统综述和荟萃分析。","authors":"Mohsen Heidary, Shirin Dashtbin, Arezoo Asadi, Parisa Asadollahi, Ali Khatib, Mohammad Amin Ebrahimi, Zahra Ghanbari, Atieh Darbandi, Roya Ghanavati, Reza Pakzad","doi":"10.2217/fmb-2023-0170","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> This study aimed to understand the current level of linezolid (LNZ) resistance in <i>Streptococcus pneumoniae</i> isolates reported over the past 10 years. <b>Material & methods:</b> An electronic search was conducted for the following keywords: ((<i>Streptococcus pneumoniae</i> [title/abstract]) OR (<i>Pneumococcus</i> [title/abstract]) OR (Pneumococci [title/abstract]) AND (linezolid [title/abstract]) OR (Zyvox [title/abstract])) OR (Zyvoxid [title/abstract])). <b>Result:</b> Out of all the studies, 80 had a cross-sectional design, while 11 followed a cohort approach. The prevalence of LNZ resistance among <i>S. pneumoniae</i> isolates ranged from 0% to 4.86%. <b>Discussion:</b> Urgent, high-powered, randomized, controlled trials with participants from endemic regions are needed to gain a comprehensive understanding of the impact on and significance of LNZ treatment to patients.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"449-459"},"PeriodicalIF":2.5000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prevalence of linezolid resistance in <i>Streptococcus pneumoniae</i> isolates: a systematic review and meta-analysis.\",\"authors\":\"Mohsen Heidary, Shirin Dashtbin, Arezoo Asadi, Parisa Asadollahi, Ali Khatib, Mohammad Amin Ebrahimi, Zahra Ghanbari, Atieh Darbandi, Roya Ghanavati, Reza Pakzad\",\"doi\":\"10.2217/fmb-2023-0170\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> This study aimed to understand the current level of linezolid (LNZ) resistance in <i>Streptococcus pneumoniae</i> isolates reported over the past 10 years. <b>Material & methods:</b> An electronic search was conducted for the following keywords: ((<i>Streptococcus pneumoniae</i> [title/abstract]) OR (<i>Pneumococcus</i> [title/abstract]) OR (Pneumococci [title/abstract]) AND (linezolid [title/abstract]) OR (Zyvox [title/abstract])) OR (Zyvoxid [title/abstract])). <b>Result:</b> Out of all the studies, 80 had a cross-sectional design, while 11 followed a cohort approach. The prevalence of LNZ resistance among <i>S. pneumoniae</i> isolates ranged from 0% to 4.86%. <b>Discussion:</b> Urgent, high-powered, randomized, controlled trials with participants from endemic regions are needed to gain a comprehensive understanding of the impact on and significance of LNZ treatment to patients.</p>\",\"PeriodicalId\":12773,\"journal\":{\"name\":\"Future microbiology\",\"volume\":\" \",\"pages\":\"449-459\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future microbiology\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.2217/fmb-2023-0170\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.2217/fmb-2023-0170","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
Prevalence of linezolid resistance in Streptococcus pneumoniae isolates: a systematic review and meta-analysis.
Aim: This study aimed to understand the current level of linezolid (LNZ) resistance in Streptococcus pneumoniae isolates reported over the past 10 years. Material & methods: An electronic search was conducted for the following keywords: ((Streptococcus pneumoniae [title/abstract]) OR (Pneumococcus [title/abstract]) OR (Pneumococci [title/abstract]) AND (linezolid [title/abstract]) OR (Zyvox [title/abstract])) OR (Zyvoxid [title/abstract])). Result: Out of all the studies, 80 had a cross-sectional design, while 11 followed a cohort approach. The prevalence of LNZ resistance among S. pneumoniae isolates ranged from 0% to 4.86%. Discussion: Urgent, high-powered, randomized, controlled trials with participants from endemic regions are needed to gain a comprehensive understanding of the impact on and significance of LNZ treatment to patients.
期刊介绍：
Future Microbiology delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this increasingly important and vast area of research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
